# To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

> **NCT00991419** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 25 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** [18F]AZD4694

## Key facts

- **NCT ID:** NCT00991419
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00991419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00991419, "To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00991419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*